Transient Myeloproliferative Disorder: A Cytogenomic Update

Area of Science:

• Hematology
• Genetics
• Neonatal Medicine

Background:

• Transient abnormal myelopoiesis (TAM), formerly TMD, is strongly linked to Down syndrome (trisomy 21).
• It occurs exclusively in neonates, often without clear clinical symptoms, but may present with hepatosplenomegaly.
• Liver hematopoietic progenitor cells are implicated as a potential origin.

Purpose of the Study:

• To review the cytogenetic, molecular, and clinical features of transient abnormal myelopoiesis (TAM).
• To explore the role of GATA1 mutations and RUNX1 gene amplification in TAM development.
• To discuss the potential progression of TAM to acute myeloid leukemia (AML).

Main Methods:

• Review of existing literature on TAM, Down syndrome, and associated genetic mutations.
• Analysis of cytogenetic and molecular genetic data related to TAM.
• Clinical case review and symptom analysis.

Main Results:

• TAM is characterized by trisomy 21, somatic GATA1 mutations, and increased megakaryoblasts.
• GATA1 mutations lead to megakaryocyte overproliferation, potentially driving progression to acute megakaryoblastic leukemia (AMKL).
• RUNX1 gene amplification on chromosome 21 is another suspected cause of TAM.

Conclusions:

• Monitoring GATA1 mutations in trisomy 21 patients can aid in early TAM diagnosis.
• While most TAM cases resolve spontaneously, some may evolve into AML.
• Understanding TAM's genetic underpinnings is crucial for managing Down syndrome-associated hematologic conditions.